According to a newly published market research report by 24LifeSciences, global pleural biopsy market was valued at USD 1.2 billion in 2024 and is projected to reach USD 1.8 billion by 2031, growing at a compound annual growth rate (CAGR) of 5.7% during the forecast period 2025-2031.
Pleural biopsy is an essential diagnostic procedure for obtaining tissue samples from the pleura - the membrane surrounding the lungs. This technique plays a pivotal role in diagnosing serious conditions including malignant mesothelioma, metastatic cancers, tuberculosis, and pleural effusions. Recent advancements have transformed pleural biopsy into a safer, more accurate diagnostic tool, significantly improving patient outcomes in thoracic medicine.
Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/15881/pleural-biopsy-market
Growing Burden of Respiratory Diseases Accelerates Market Demand
The market growth is primarily driven by the increasing prevalence of lung cancer, mesothelioma, and tuberculous pleuritis worldwide. With approximately 1.8 million new lung cancer cases diagnosed annually, the need for accurate pleural diagnostics continues to rise sharply. The expanding elderly population, more susceptible to pleural diseases, further fuels this demand.
Hospitals remain the largest end-users of pleural biopsy procedures, a trend expected to continue due to the acute nature of these diagnostic interventions requiring specialized infrastructure and immediate access to thoracic surgery teams.
Technological Revolution in Biopsy Techniques
Innovations in image-guided biopsy systems and medical thoracoscopy have significantly improved procedural outcomes. Modern techniques now achieve diagnostic accuracy exceeding 90%, while minimizing patient discomfort and complication risks. The market has witnessed rapid adoption of CT-guided and ultrasound-assisted pleural biopsies, which now account for 65% of procedures in developed healthcare systems.
Emerging robotic-assisted biopsy systems promise to further revolutionize the field, with commercial launches anticipated by 2026. These advancements are expanding suitable patient populations and driving procedural volumes globally.
Market Challenges: Procedure Risks and Access Barriers
Despite strong growth prospects, the pleural biopsy market faces several constraints:
-
Procedure-related complications including pneumothorax (5-15% incidence) and hemorrhage
-
High equipment costs limiting adoption in developing regions
-
Specialist shortage, particularly in rural healthcare settings
-
Alternative diagnostic methods like liquid biopsies gaining traction
The requirement for specialized training and the development of molecular diagnostics continue to present both challenges and opportunities for market participants.
Get the Complete Report & Table of Contents: https://www.24lifesciences.com/pleural-biopsy-market-15881
North America Leads Global Market with Advanced Healthcare Infrastructure
North America currently dominates the pleural biopsy market, holding 38% of global revenue share. This leadership position stems from:
-
High incidence of mesothelioma and lung cancers
-
Advanced healthcare infrastructure and early technology adoption
-
Strong reimbursement policies supporting diagnostic procedures
-
Concentration of key market players and research institutions
The Asia-Pacific region is projected to grow at the fastest rate, driven by improving healthcare access and rising disease awareness across emerging economies.
Hospitals Dominate as Primary Procedure Setting
By end-user, hospitals accounted for 64% of pleural biopsy procedures in 2023. This predominance reflects the need for comprehensive diagnostic infrastructure and immediate access to specialist care. However, cancer research institutes are emerging as high-growth segments, expanding at a 11.3% CAGR due to increased mesothelioma research funding.
Among procedure types, thoracoscopic biopsy is establishing itself as the gold standard, offering superior visualization and tissue sampling capabilities compared to traditional needle biopsies.
Competitive Landscape: Global Leaders and Specialized Innovators
The global pleural biopsy market features a mix of established medical technology giants and specialized diagnostic companies. The top five players collectively hold 58% market share, with Olympus Corporation leading at 19% revenue share.
Key companies profiled in the report include:
-
Olympus Corporation
-
Boston Scientific Corporation
-
B. Braun Melsungen AG
-
KARL STORZ GmbH & Co. KG
-
Medtronic plc
-
Fujifilm Holdings Corporation
-
Cook Medical Incorporated
-
and More
Recent strategic moves include Boston Scientific's acquisition of thoracic diagnostics assets and Fujifilm's partnerships with leading cancer centers, reflecting the dynamic nature of this competitive landscape.
Emerging Opportunities in Developing Markets and Hybrid Diagnostics
Significant growth potential exists in Asia-Pacific and Latin American markets where healthcare infrastructure development coincides with rising disease burdens. Additionally, the integration of pleural biopsy with rapid molecular testing creates new possibilities for comprehensive diagnostic solutions that combine histological analysis with therapeutic targeting.
The development of single-use biopsy devices, now comprising 43% of product offerings, addresses growing concerns about procedure safety and cross-contamination risks, opening new avenues for market expansion.
Access the Full Report
Download a Free Sample Report (PDF):
https://www.24lifesciences.com/download-sample/15881/pleural-biopsy-market
Get the Complete Report & Table of Contents:
https://www.24lifesciences.com/pleural-biopsy-market-15881
About 24LifeSciences
24LifeSciences is a leading provider of market intelligence and strategic research reports across pharmaceuticals, biotechnology, medical devices, and healthcare technologies. Our reports are designed to support data-driven decision-making for manufacturers, healthcare providers, investors, consultants, and policy makers worldwide.
Follow us on LinkedIn:
https://www.linkedin.com/company/lifesciences24/